Outlook Therapeutics, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Outlook Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 19, 2026). It closed at $0.56, 77.2% below its 52-week high and below its 200-day average, which is falling.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. More about the company

$0.56

+0.53% today

$137M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is OTLK early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 35w

S1 14w

S4 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 4w → S4 10w → S1 6w → S4 10w → S1 6w → S4 4w → S3 2w → S4 7w → S1 5w → S4 35w → S1 14w → S2 2w → S3 2w → S4 9w → S1 3w → S2 3w → S1 1w → S4 20w → S1 6w → S2 7w → S3 7w → S4 1w current

Total tracked: 164 weeks across 23 stage runs.

OTLK among Biotechnology390th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…390	OTLKOutlook Therapeutics, Inc.	Stage 4 · wk 1	19	−14.8%

vs 52W High

-77.2%

$0.20 lo$2.47 hi

77.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-15.1%

200 DMA: $0.66 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.38x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.8%

-59.9%

+96.5%

YTD

-14.5%

-60.0%

Scan Membership

Breakout Watch

Latest: 2023-05-25

6 appearances in last 60 days. First seen: 2019-03-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.38x

2026-10-21S4

Wk 1 · Vol 0.26x

2026-10-20S4

Wk 1 · Vol 0.28x

2026-10-19S43→4

Wk 1 · Vol 0.22x

2026-10-16S3

Wk 7 · Vol 0.26x

2026-10-15S3

Wk 7 · Vol 0.46x

2026-10-14S3

Wk 7 · Vol 0.81x

2026-10-13S3

Wk 7 · Vol 0.27x

2026-10-12S3

Wk 6 · Vol 0.19x

2026-10-09S3

Wk 6 · Vol 0.30x

2026-10-08S3

Wk 6 · Vol 0.32x

2026-10-07S3

Wk 6 · Vol 0.32x

Moving averages & range

50 DMA

$0.63

200 DMA

$0.66

52W High

$2.47

52W Low

$0.20

5D Low

$0.49

Resistance levels (recent highs)

20d High

$0.64

60d High

$1.15

120d High

$1.83

250d High

$2.47

Next resistance

+13.5%

to 20d High

Dividend Yield

0.00%

P/B -10.1

Outlook Therapeutics: quick answers

What stage is Outlook Therapeutics in?

As of Oct 22, 2026, Outlook Therapeutics (OTLK) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 19, 2026 and is in its first week there. What the four stages mean

Is Outlook Therapeutics in an uptrend?

No. Outlook Therapeutics is in a Stage 4 downtrend. It trades 15.1% below its 200-day average, which is falling.

How far is Outlook Therapeutics from its 52-week high?

Outlook Therapeutics closed at $0.56 on Oct 22, 2026, 77.2% below its 52-week high of $2.47. Its 52-week low is $0.20.

How has Outlook Therapeutics performed over the past year?

As of Oct 22, 2026, Outlook Therapeutics is down 60.0% over the past year and down 14.5% so far in 2026.

Which sector and industry is Outlook Therapeutics in?

Outlook Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.